---
title: "OSR Holdings, Inc. (OSRH.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/OSRH.US.md"
symbol: "OSRH.US"
name: "OSR Holdings, Inc."
industry: "Biotechnology"
datetime: "2026-05-19T21:36:07.919Z"
locales:
  - [en](https://longbridge.com/en/quote/OSRH.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/OSRH.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/OSRH.US.md)
---

# OSR Holdings, Inc. (OSRH.US)

## Company Overview

OSR Holdings, Inc., a healthcare holding company, develops a portfolio of therapies and healthcare solutions in the United States, Germany, Switzerland, and South Korea. The company develops immunotherapy products, including VXM01, an immuno-oncology candidate for glioblastoma completed phase 2 clinical trial, as well as preclinical stage products, such as VXM04 to treat mesothelin; VXM06 for the treatment of Wilms Tumor Protein (WT1); VXM08 for Carcinoembryonic antigen (CEA); and VXM10 for PD-L1. It is also developing design-augmented (DA) biologics comprising DRT-102, a clinical-stage asset for spinal fusion; and DRT-101, a pre-clinical stage asset for osteoarthritis. In addition, the company distributes neurovascular intervention medical device and systems.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.osr-holdings.com](https://www.osr-holdings.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:14.000Z

**Overall: C (0.48)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 165 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 1864.71% |  |
| Net Profit YoY | 8.60% |  |
| P/B Ratio | 0.17 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 17314309.44 |  |
| Revenue | 2628591.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -10.63% | D |
| Profit Margin | -363.30% | E |
| Gross Margin | 33.11% | C |
| Revenue YoY | 1864.71% | A |
| Net Profit YoY | 8.60% | C |
| Total Assets YoY | -1.35% | D |
| Net Assets YoY | -3.70% | D |
| Cash Flow Margin | 55.14% | C |
| OCF YoY | 1864.71% | A |
| Turnover | 0.02 | E |
| Gearing Ratio | 26.02% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - OSR Holdings, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "1864.71%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "8.60%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "0.17",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "17314309.44",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "2628591.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-10.63%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "-363.30%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "33.11%",
          "rating": "C"
        },
        {
          "name": "Revenue YoY",
          "value": "1864.71%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "8.60%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "-1.35%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "-3.70%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "55.14%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "1864.71%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.02",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "26.02%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -1.81 | 235/386 | - | - | - |
| PB | 0.17 | 7/386 | 0.26 | 0.18 | 0.15 |
| PS (TTM) | 6.59 | 135/386 | 135.28 | 118.50 | 6.68 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-05T04:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Hold | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 0.51 |
| Highest Target | 10.00 |
| Lowest Target | 10.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/OSRH.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/OSRH.US/norm.md)
- [Related News](https://longbridge.com/en/quote/OSRH.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/OSRH.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**